Literature DB >> 16464432

Refinement of techniques for the propagation of Leishmania donovani in hamsters.

Susan Wyllie1, Alan H Fairlamb.   

Abstract

Improved animal models are urgently required for drug and vaccine development against visceral leishmaniasis. Here we report refinements to the hamster model of infection that reduce the severity of the disease as well as the number of animals required to maintain infection while improving parasite yields. A comparison between infection via the intracardiac and intraperitoneal routes showed that the less commonly used intraperitoneal route is the simpler and preferred method. The KAtex latex agglutination test for visceral leishmaniasis accurately detected Leishmania donovani antigen in hamster urine as early as 6 weeks post-inoculation. With modification, this assay could be an important tool in the evaluation of experimental drugs and vaccines.

Entities:  

Mesh:

Year:  2006        PMID: 16464432     DOI: 10.1016/j.actatropica.2006.01.004

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  13 in total

1.  The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis.

Authors:  Susan Wyllie; Stephen Patterson; Laste Stojanovski; Frederick R C Simeons; Suzanne Norval; Robert Kime; Kevin D Read; Alan H Fairlamb
Journal:  Sci Transl Med       Date:  2012-02-01       Impact factor: 17.956

2.  Setting new immunobiological parameters in the hamster model of visceral leishmaniasis for in vivo testing of antileishmanial compounds.

Authors:  M A Dea-Ayuela; S Rama-Iñiguez; J M Alunda; F Bolás-Fernandez
Journal:  Vet Res Commun       Date:  2007-01-19       Impact factor: 2.459

3.  Leishmania subtilisin is a maturase for the trypanothione reductase system and contributes to disease pathology.

Authors:  Ryan K Swenerton; Giselle M Knudsen; Mohammed Sajid; Ben L Kelly; James H McKerrow
Journal:  J Biol Chem       Date:  2010-07-30       Impact factor: 5.157

4.  Reduced hamster usage and stress in propagating Leishmania chagasi promastigotes using cryopreservation and saphenous vein inoculation.

Authors:  Soi Meng Lei; Amanda E Ramer-Tait; Rebecca R Dahlin-Laborde; Kathleen Mullin; Jeffrey K Beetham
Journal:  J Parasitol       Date:  2010-02       Impact factor: 1.276

5.  Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis.

Authors:  Meghan R Perry; Susan Wyllie; Andrea Raab; Joerg Feldmann; Alan H Fairlamb
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-28       Impact factor: 11.205

6.  The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis.

Authors:  Stephen Patterson; Susan Wyllie; Laste Stojanovski; Meghan R Perry; Frederick R C Simeons; Suzanne Norval; Maria Osuna-Cabello; Manu De Rycker; Kevin D Read; Alan H Fairlamb
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

7.  New insights into experimental visceral leishmaniasis: Real-time in vivo imaging of Leishmania donovani virulence.

Authors:  Guilherme D Melo; Sophie Goyard; Hervé Lecoeur; Eline Rouault; Pascale Pescher; Laurence Fiette; Alexandre Boissonnas; Paola Minoprio; Thierry Lang
Journal:  PLoS Negl Trop Dis       Date:  2017-09-25

8.  Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis.

Authors:  Michael G Thomas; Manu De Rycker; Myriam Ajakane; Sébastian Albrecht; Ana Isabel Álvarez-Pedraglio; Markus Boesche; Stephen Brand; Lorna Campbell; Juan Cantizani-Perez; Laura A T Cleghorn; Royston C B Copley; Sabrinia D Crouch; Alain Daugan; Gerard Drewes; Santiago Ferrer; Sonja Ghidelli-Disse; Silvia Gonzalez; Stephanie L Gresham; Alan P Hill; Sean J Hindley; Rhiannon M Lowe; Claire J MacKenzie; Lorna MacLean; Sujatha Manthri; Franck Martin; Juan Miguel-Siles; Van Loc Nguyen; Suzanne Norval; Maria Osuna-Cabello; Andrew Woodland; Stephen Patterson; Imanol Pena; Maria Teresa Quesada-Campos; Iain H Reid; Charlotte Revill; Jennifer Riley; Jose Ramon Ruiz-Gomez; Yoko Shishikura; Frederick R C Simeons; Alasdair Smith; Victoria C Smith; Daniel Spinks; Laste Stojanovski; John Thomas; Stephen Thompson; Tim Underwood; David W Gray; Jose M Fiandor; Ian H Gilbert; Paul G Wyatt; Kevin D Read; Timothy J Miles
Journal:  J Med Chem       Date:  2018-12-20       Impact factor: 7.446

9.  Body weight as a determinant of clinical evolution in hamsters (Mesocricetus auratus) infected with Leishmania (Viannia) panamensis.

Authors:  Angela María Gómez-Galindo; Lucy Gabriela Delgado-Murcia
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2013 Sep-Oct       Impact factor: 1.846

10.  The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis.

Authors:  Stephen Patterson; Susan Wyllie; Suzanne Norval; Laste Stojanovski; Frederick Rc Simeons; Jennifer L Auer; Maria Osuna-Cabello; Kevin D Read; Alan H Fairlamb
Journal:  Elife       Date:  2016-05-24       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.